依维莫司
医学
安慰剂
神经内分泌肿瘤
危险系数
内科学
临床终点
不利影响
胃肠病学
肿瘤科
无进展生存期
随机对照试验
外科
癌症研究
胰腺神经内分泌肿瘤
置信区间
胰腺癌
化疗
病理
替代医学
作者
James C. Yao,Manisha H. Shah,Tetsuhide Ito,Catherine Lombard Bohas,Edward M. Wolin,Eric Van Cutsem,Timothy J. Hobday,Takuji Okusaka,Jaume Capdevila,Elisabeth G.E. de Vries,Paola Tomassetti,Marianne Pavel,Sakina Hoosen,Tomas Haas,Jeremie Lincy,David Lebwohl,Kjell Öberg
标识
DOI:10.1056/nejmoa1009290
摘要
Everolimus, an oral inhibitor of mammalian target of rapamycin (mTOR), has shown antitumor activity in patients with advanced pancreatic neuroendocrine tumors, in two phase 2 studies. We evaluated the agent in a prospective, randomized, phase 3 study.
科研通智能强力驱动
Strongly Powered by AbleSci AI